Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2017

Study Completion Date

August 11, 2020

Conditions
Glioblastoma MultiformeAnaplastic Astrocytoma
Interventions
DRUG

Super-Selective Intraarterial Intracranial Infusion of Temozolomide

A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)

Trial Locations (1)

10065

Lenox Hill Brain Tumor Center, New York

All Listed Sponsors
collaborator

Feinstein Institute for Medical Research

OTHER

collaborator

Hofstra North Shore

OTHER

lead

Northwell Health

OTHER